Secukinumab Clinical Trials (2026): 170 Studies for Psoriasis & Psoriatic Arthritis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
170 Secukinumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 63 indications (including Psoriasis & Psoriatic Arthritis) and 76,752 total planned enrollment. 79 Phase 3 Secukinumab trials and 23 Phase 2, 37 Phase 4 are listed. 20 Secukinumab clinical trials are actively recruiting at 11 U.S. sites across 7 states. Most recent activity: NCT06751238 (Dec 2032).
Where to Participate: All Secukinumab Trial Sites in the U.S. (11 sites across 7 states)
Every actively recruiting Secukinumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Rheumatology Associates of South Florida | Boca Raton33486 | NCT04638647 | Map |
| FL | University of Florida | Gainesville32610 8068 | NCT06751238 | Map |
| FL | FL Medical Clinic Orlando Health | Zephyrhills33542 | NCT04638647 | Map |
| IL | Ann and Robert H Lurie Childs Hosp | Chicago60611 | NCT06751238 | Map |
| NC | Levine Childrens Hospital | Charlotte28203 | NCT06751238 | Map |
| NC | Duke University Health System | Durham27710 | NCT07237594 | Map |
| OH | Cincinnati Childrens Hospital | Cincinnati45229 | NCT06751238 | Map |
| OH | Univ Hosp Cleveland Medical Center | Cleveland44106-5028 | NCT06751238 | Map |
| OR | Legacy Emanuel Research Hosp Portland | Portland97232 | NCT06751238 | Map |
| PA | Childrens Hosp Pittsburgh UPMC | Pittsburgh15224 | NCT06751238 | Map |
| TX | Texas Arthritis Center | El Paso79902 | NCT06751238 | Map |
Secukinumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | available | Total |
|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | 2 | ||||||
| P1 | 2 | 1 | 5 | 1 | 9 | ||||
| P1/P2 | 2 | 2 | |||||||
| P2 | 15 | 4 | 2 | 2 | 23 | ||||
| P3 | 3 | 64 | 7 | 2 | 3 | 79 | |||
| P4 | 4 | 1 | 19 | 1 | 5 | 7 | 37 | ||
| N/A | 7 | 10 | 1 | 18 |
Recruiting Secukinumab clinical trials (20)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06751238 | PKStudy to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). | P1 | Juvenile Psoriatic Arthritis | 20 | Sep 2025 |
| NCT07237594 | REPLAYIL-17 Blockade to Decrease irAEs (REPLAY) | P1 | Metastatic Melanoma | 4 | Mar 2026 |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | Psoriasis | 10 | Aug 2026 |
| NCT04638647 | Secukinumab Open Label Roll-over Extension Protocol | P4 | Autoimmunity, Inflammation | 1,000 | Dec 2020 |
| NCT07477795 | STARSPhase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients | P2 | Takayasu Arteritis | 52 | Apr 2026 |
| NCT07489573 | Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa | P4 | Hidradenitis Suppurativa (HS) | 36 | Jun 2026 |
| NCT07485764 | Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients | P4 | Psoriasis | 186 | Jun 2026 |
| NCT06398106 | HELIOSProactive TDM Versus Standard Use of Biologics in Psoriasis | P4 | Psoriasis Vulgaris | 210 | Dec 2024 |
| NCT06833112 | IL-17Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis | P4 | Ankylosing Spondylitis | 10 | Feb 2025 |
| NCT04239859 | Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis | P4 | Plaque Psoriasis | 40 | Jan 2024 |
| NCT05503875 | Immunoclassification of Psoriasis: a Strategy for Precision Medicine | N/A | Immunoclassification | 100 | Jan 2023 |
| NCT06707246 | A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients | N/A | Hidradenitis Suppurativa | 60 | Dec 2024 |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | Rheumatic Disease | 80 | Sep 2025 |
| NCT07243782 | Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea | — | Hidradenitis Suppurativa | 76 | Dec 2025 |
| NCT06786936 | ELATEEvaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms | — | Psoriatic Arthritis | 50 | Jun 2025 |
| NCT07261072 | Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS | P4 | Hidradenitis Suppurativa (HS) | 30 | Dec 2025 |
| NCT06905288 | ONSETReal-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. | — | Ankylosing Spondylitis | 70 | Apr 2025 |
| NCT05303285 | A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis | P4 | Ankylosing Spondylitis (AS) | 100 | Jun 2024 |
| NCT07109765 | Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa | — | Hidradenitis Suppurativa (HS) | 50 | Jun 2025 |
| NCT06926192 | Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa | — | Hidradenitis Suppurativa (HS) | 100 | Jan 2020 |
Secukinumab clinical trials by indication
Psoriasis (34)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07352566 | — | P4 | not yet recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT07485764 | — | P4 | not yet recruiting | Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients |
| NCT07254325 | — | P1 | active not recruiting | Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers |
| NCT06398652 | — | P3 | completed | Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis |
| NCT06110676 | Psoriasis | P3 | unknown | A Study to Evaluate the Efficacy and Safety of LZM012 |
| NCT04535999 | — | P4 | completed | Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) |
| NCT04717466 | — | P4 | completed | Brain Changes in Psoriasis After Secukinumab Treatment |
| NCT04340076 | BeNeBio | P4 | completed | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis |
| + 26 more, see All trials below. | ||||
Psoriatic Arthritis (18)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06786936 | ELATE | N/A | recruiting | Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms |
| NCT04610476 | — | P3 | unknown | Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis |
| NCT04632927 | AgAIN | P3 | completed | Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment |
| NCT06600009 | FLYWAY | N/A | completed | Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database |
| NCT04967950 | — | P1 | unknown | An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients |
| NCT03623867 | — | P4 | completed | PsA Secukinumab XCT Structural Progression Study |
| NCT04887597 | EBIO | P4 | unknown | EBIO - Enthesitis Biopsy Study |
| NCT03955861 | — | N/A | completed | Ultrasound Enthesitis Response in Psoriatic Arthritis |
| + 10 more, see All trials below. | ||||
Plaque Psoriasis (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04239859 | — | P4 | not yet recruiting | Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis |
| NCT06945107 | — | P3 | active not recruiting | A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy |
| NCT03020199 | STEPin | P4 | completed | Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis |
| NCT05891964 | — | P4 | completed | Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital. |
| NCT05650060 | — | N/A | completed | Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis |
| NCT04237116 | pINPOINt | P3 | terminated | A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) |
| NCT03589885 | MATURE | P3 | completed | Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis |
| NCT03055494 | ObePso-S | P4 | completed | Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients |
| + 5 more, see All trials below. | ||||
Ankylosing Spondylitis (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06833112 | IL-17 | P4 | not yet recruiting | Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis |
| NCT06905288 | ONSET | N/A | recruiting | Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. |
| NCT05527444 | — | P4 | unknown | The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients |
| NCT04156620 | — | P3 | completed | Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA |
| NCT03350815 | ASLeap | P4 | completed | Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis |
| NCT02763046 | ASTRUM | P4 | completed | Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis |
| NCT02750592 | — | P3 | completed | Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis |
| NCT01358175 | MEASURE 1 | P3 | completed | 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis |
Hidradenitis Suppurativa (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06707246 | — | N/A | recruiting | A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients |
| NCT07243782 | — | N/A | recruiting | Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea |
| NCT04179175 | — | P3 | active not recruiting | Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa |
| NCT03713619 | SUNSHINE | P3 | completed | This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). |
| NCT03713632 | SUNRISE | P3 | completed | Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) |
| NCT03099980 | — | Early P1 | completed | Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa |
Hidradenitis Suppurativa (HS) (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07489573 | — | P4 | recruiting | Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa |
| NCT07261072 | — | P4 | not yet recruiting | Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS |
| NCT07109765 | — | N/A | recruiting | Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa |
| NCT06926192 | — | N/A | recruiting | Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa |
| NCT05583604 | — | N/A | available | Managed Access Programs for AIN457, Secukinumab |
Rheumatoid Arthritis (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05080218 | COVER | P4 | completed | COVID-19 VaccinE Response in Rheumatology Patients |
| NCT01377012 | REASSURE | P3 | completed | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents |
| NCT01770379 | REASSURE2 | P3 | terminated | Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. |
| NCT01426789 | RA | P2 | completed | A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients |
| NCT01359943 | — | P2 | completed | Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate |
Psoriasis Vulgaris (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06398106 | HELIOS | P4 | recruiting | Proactive TDM Versus Standard Use of Biologics in Psoriasis |
| NCT03307447 | OCT | P4 | unknown | Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). |
| NCT03149900 | BIOMARKER | N/A | completed | Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients |
| NCT03828643 | — | N/A | completed | Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis |
Axial Spondyloarthritis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03445845 | ROC-SPA | P4 | completed | Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis |
| NCT03906136 | AScalate | P3 | completed | AScalate: Treat-to-target in Axial Spondyloarthritis |
| NCT05677542 | — | N/A | completed | Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study |
| NCT03639740 | TRACE | P4 | unknown | Treat-to-target With Secukinumab in Axial Spondyloarthritis |
Moderate to Severe Plaque-type Psoriasis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01544595 | — | P3 | completed | Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab |
| NCT01555125 | FEATURE | P3 | completed | First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks |
| NCT02474069 | GAIN | P3 | completed | Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis |
| NCT01365455 | ERASURE | P3 | completed | Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year |
Juvenile Psoriatic Arthritis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06751238 | PK | P1 | recruiting | Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). |
| NCT03769168 | ERA | P3 | completed | An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) |
| NCT03031782 | ERA | P3 | completed | Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) |
Giant Cell Arteritis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05380453 | GigAINt | P3 | completed | Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission |
| NCT06130540 | — | P1 | completed | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR |
| NCT03765788 | TitAIN | P2 | completed | A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis |
Chronic Plaque Psoriasis (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03536884 | BE RADIANT | P3 | completed | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT02690701 | VIP-S | P4 | completed | Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis |
| NCT01358578 | FIXTURE | P3 | completed | Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis |
Spondylitis, Ankylosing (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01863732 | MEASURE 1 ext | P3 | completed | Extension in AS: Sustainability of Benefits, Safety and Tolerability |
| NCT02159053 | MEASURE4 | P3 | completed | 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis |
| NCT02008916 | MEASURE 3 | P3 | completed | 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients |
Polymyalgia Rheumatica (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06331312 | REPLENISH-EXT | P3 | active not recruiting | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) |
| NCT05767034 | REPLENISH | P3 | completed | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) |
Rotator Cuff Tendinopathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05722522 | — | P3 | terminated | Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
| NCT05758415 | — | P3 | terminated | Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
Non-radiographic Axial Spondyloarthritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05622708 | — | P4 | active not recruiting | A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission |
| NCT04732117 | — | P3 | completed | Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis |
Tendinopathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05569174 | UnchAIN | P3 | completed | Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy |
| NCT03344640 | — | P2 | completed | Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy |
Lupus Nephritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04181762 | SELUNE | P3 | terminated | Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis |
| NCT05232864 | — | P3 | terminated | Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis |
Pyoderma Gangrenosum (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04274166 | — | P2 | withdrawn | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum |
| NCT02733094 | — | P1/P2 | completed | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum |
Moderate to Severe Chronic Plaque-type Psoriasis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03668613 | — | P3 | completed | Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis |
| NCT03504852 | — | P3 | completed | Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis |
Plaque-type Psoriasis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01636687 | JUNCTURE | P3 | completed | Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) |
| NCT01412944 | STATURE | P3 | completed | Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis |
Metastatic Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07237594 | REPLAY | P1 | recruiting | IL-17 Blockade to Decrease irAEs (REPLAY) |
Takayasu Arteritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07477795 | STARS | P2 | not yet recruiting | Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients |
Rheumatic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07138898 | — | P2 | not yet recruiting | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
Ankylosing Spondylitis (AS) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05303285 | — | P4 | recruiting | A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis |
Immunoclassification (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05503875 | — | N/A | recruiting | Immunoclassification of Psoriasis: a Strategy for Precision Medicine |
Active Peripheral Spondyloarthritis (pSpA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05206591 | CAIN457X12301 | P3 | withdrawn | Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). |
Thyroid Eye Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04737330 | ORBIT | P3 | terminated | A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) |
Giant Cell Arteritis (GCA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04930094 | GCAptAIN | P3 | completed | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) |
Congenital Ichthyosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04996485 | — | P4 | unknown | Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children |
Autoimmunity, Inflammation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04638647 | — | P4 | recruiting | Secukinumab Open Label Roll-over Extension Protocol |
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04300296 | PRELUDE | P2 | completed | PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus |
COVID 19 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04403243 | COLORIT | P2 | completed | COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 |
Discoid Lupus Erythematosus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03866317 | — | P2 | withdrawn | A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus |
Generalized Pustular Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06391996 | — | N/A | completed | Biologic Therapy for Generalized Pustular Psoriasis |
Necrobiosis Lipoidica Diabeticorum (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03791060 | NLD | P2 | terminated | Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD) |
Dermatitis, Atopic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03568136 | Secu_in_AD | P2 | completed | Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis |
Papulopustular Rosacea (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03079531 | — | P1/P2 | completed | Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea |
Ichthyosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03041038 | — | P2 | completed | The Efficacy and Safety of Secukinumab in Patients With Ichthyoses |
Ankylosing Spondyloarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02896127 | — | P3 | completed | Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis |
Vitiligo (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05676333 | — | P4 | completed | Secukinumab in Active Non-segmental Vitiligo |
Axial Psoratic Arthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02721966 | MAXIMISE | P3 | completed | Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement |
Non-radiographic Spondyloarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02696031 | PREVENT | P3 | completed | Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis |
Allergic Contact Dermatitits (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02778711 | — | P3 | unknown | Anti-IL-17 a New Treatment for Contact Dermatititis |
Atopic Dermatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02594098 | — | P2 | completed | Secukinumab for Treatment of Atopic Dermatitis |
Alopecia Areata (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02599129 | — | P2 | terminated | A Study of Secukinumab for the Treatment of Alopecia Areata |
Chronic Severe Plaque-type Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02471144 | — | P3 | completed | Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis |
Arthritis, Psoriatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02294227 | FUTURE 4 | P3 | completed | 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis |
Plaque Type Psorisis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02394561 | SUPREME | P3 | completed | A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) |
Chronic Scalp Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02267135 | SCALP | P3 | completed | Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis |
Spondylarthropathies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03358134 | MoA aIL-17 | P3 | completed | Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis |
Type 1 Diabetes Mellitus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02044848 | — | P2 | terminated | Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus |
Chronic Plaque Type Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02074982 | — | P3 | completed | Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis |
Palmoplantar Pustular Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02008890 | — | P3 | completed | Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab |
Chronic Plaque-type Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01828086 | — | P1 | completed | Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis |
Moderate to Severe Nail Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01807520 | TRANSFIGURE | P3 | completed | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis |
Moderate to Severe Palmoplantar Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01806597 | GESTURE | P3 | completed | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis |
Anklyosing Spondylitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01649375 | MEASURE2 | P3 | completed | 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis |
Asthma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01478360 | — | P2 | terminated | Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01539213 | OFM ISF | P1 | completed | Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg |
Psoriasis, Plaque-type Psoriasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01537432 | — | P2 | completed | Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients |
Dry Eye (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01250171 | AIN457 | P2 | completed | The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients |
Secukinumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| HELIOS | NCT06398106 | P4 | recruiting | Psoriasis Vulgaris | 210 | — |
| IL-17 | NCT06833112 | P4 | not yet recruiting | Ankylosing Spondylitis | 10 | — |
| BeNeBio | NCT04340076 | P4 | completed | Psoriasis | 244 | PMID 34656148 |
| ROC-SPA | NCT03445845 | P4 | completed | Axial Spondyloarthritis | 300 | PMID 39260856 |
| COVER | NCT05080218 | P4 | completed | Rheumatoid Arthritis | 841 | — |
| STEPin | NCT03020199 | P4 | completed | Plaque Psoriasis | 196 | PMID 41881197 |
| EBIO | NCT04887597 | P4 | unknown | Psoriatic Arthritis | 10 | — |
| METABOLYX | NCT03440736 | P4 | completed | Psoriasis | 781 | — |
| OCT | NCT03307447 | P4 | unknown | Psoriasis Vulgaris | 30 | — |
| ASLeap | NCT03350815 | P4 | completed | Ankylosing Spondylitis | 322 | PMID 39133200 |
| INTERCEPT | NCT04488185 | P4 | withdrawn | Psoriasis | 0 | PMID 25881759 |
| TRACE | NCT03639740 | P4 | unknown | Axial Spondyloarthritis | 88 | PMID 41963078 |
| ASTRUM | NCT02763046 | P4 | completed | Ankylosing Spondylitis | 211 | PMID 38846755 |
| ObePso-S | NCT03055494 | P4 | completed | Plaque Psoriasis | 102 | PMID 41774505 |
| PROSE | NCT02752776 | P4 | completed | Plaque Psoriasis | 1,660 | PMID 34273904 |
| VIP-S | NCT02690701 | P4 | completed | Chronic Plaque Psoriasis | 91 | PMID 32088207 |
| CAIN457X12301 | NCT05206591 | P3 | withdrawn | Active Peripheral Spondyloarthritis (pSpA) | 0 | — |
| REPLENISH-EXT | NCT06331312 | P3 | active not recruiting | Polymyalgia Rheumatica | 161 | — |
| GigAINt | NCT05380453 | P3 | completed | Giant Cell Arteritis | 151 | — |
| GCAptAIN | NCT04930094 | P3 | completed | Giant Cell Arteritis (GCA) | 354 | — |
| REPLENISH | NCT05767034 | P3 | completed | Polymyalgia Rheumatica | 381 | PMID 39400109 |
| Psoriasis | NCT06110676 | P3 | unknown | Psoriasis | 918 | — |
| UnchAIN | NCT05569174 | P3 | completed | Tendinopathy | 62 | — |
| ERA | NCT03769168 | P3 | completed | Juvenile Psoriatic Arthritis | 55 | — |
| AgAIN | NCT04632927 | P3 | completed | Psoriatic Arthritis | 119 | — |
| SELUNE | NCT04181762 | P3 | terminated | Lupus Nephritis | 275 | PMID 37528520 |
| BE RADIANT | NCT03536884 | P3 | completed | Chronic Plaque Psoriasis | 743 | PMID 37182701 |
| ORBIT | NCT04737330 | P3 | terminated | Thyroid Eye Disease | 28 | — |
| AScalate | NCT03906136 | P3 | completed | Axial Spondyloarthritis | 304 | PMID 32998926 |
| SUNSHINE | NCT03713619 | P3 | completed | Hidradenitis Suppurativa | 544 | PMID 40372667 |
| SUNRISE | NCT03713632 | P3 | completed | Hidradenitis Suppurativa | 545 | PMID 39425517 |
| pINPOINt | NCT04237116 | P3 | terminated | Plaque Psoriasis | 10 | — |
| PREVENT | NCT02696031 | P3 | completed | Non-radiographic Spondyloarthritis | 555 | PMID 40489668 |
| PDUS | NCT02662985 | P3 | completed | Psoriatic Arthritis | 166 | PMID 34528079 |
| ERA | NCT03031782 | P3 | completed | Juvenile Psoriatic Arthritis | 86 | PMID 40953957 |
| MATURE | NCT03589885 | P3 | completed | Plaque Psoriasis | 122 | — |
| OASIS-2 | NCT03535194 | P3 | completed | Psoriasis | 1,484 | PMID 38251498 |
| EXCEED 1 | NCT02745080 | P3 | completed | Psoriatic Arthritis | 853 | PMID 32386593 |
| ACHILLES | NCT02771210 | P3 | completed | Psoriatic Arthritis | 204 | PMID 34730795 |
| MAXIMISE | NCT02721966 | P3 | completed | Axial Psoratic Arthritis | 503 | PMID 37094184 |
| FUTURE5 | NCT02404350 | P3 | completed | Psoriatic Arthritis | 997 | PMID 29550766 |
| FUTURE 2 | NCT01752634 | P3 | completed | Psoriatic Arthritis | 397 | PMID 38446397 |
| ECLIPSE | NCT03090100 | P3 | completed | Psoriasis | 1,048 | PMID 37906417 |
| MEASURE2 | NCT01649375 | P3 | completed | Anklyosing Spondylitis | 219 | PMID 27582421 |
| CLARITY | NCT02826603 | P3 | completed | Plaque Psoriasis | 1,114 | PMID 30334147 |
| ALLURE | NCT02748863 | P3 | completed | Psoriasis | 214 | PMID 33896356 |
| MEASURE 1 ext | NCT01863732 | P3 | completed | Spondylitis, Ankylosing | 274 | PMID 33324394 |
| FUTURE 1 ext | NCT01892436 | P3 | completed | Psoriatic Arthritis | 460 | PMID 30167329 |
| MEASURE4 | NCT02159053 | P3 | completed | Spondylitis, Ankylosing | 350 | PMID 33722947 |
| FUTURE 4 | NCT02294227 | P3 | completed | Arthritis, Psoriatic | 341 | PMID 31228101 |
| MEASURE 3 | NCT02008916 | P3 | completed | Spondylitis, Ankylosing | 226 | PMID 29273067 |
| MoA aIL-17 | NCT03358134 | P3 | completed | Spondylarthropathies | 20 | — |
| SUPREME | NCT02394561 | P3 | completed | Plaque Type Psorisis | 434 | — |
| OPTIMISE | NCT02409667 | P3 | completed | Plaque Psoriasis | 16,487 | — |
| IPSI-PSO | NCT02595970 | P3 | completed | Psoriasis | 120 | — |
| TRANSFIGURE | NCT01807520 | P3 | completed | Moderate to Severe Nail Psoriasis | 198 | — |
| GESTURE | NCT01806597 | P3 | completed | Moderate to Severe Palmoplantar Psoriasis | 205 | — |
| JUNCTURE | NCT01636687 | P3 | completed | Plaque-type Psoriasis | 182 | PMID 25243910 |
| FEATURE | NCT01555125 | P3 | completed | Moderate to Severe Plaque-type Psoriasis | 177 | — |
| GAIN | NCT02474069 | P3 | completed | Moderate to Severe Plaque-type Psoriasis | 772 | — |
| PSORITUS | NCT02362789 | P3 | completed | Psoriasis | 132 | — |
| SIGNATURE | NCT01961609 | P3 | completed | Psoriasis | 235 | — |
| PRIME | NCT02474082 | P3 | completed | Psoriasis | 202 | — |
| CARIMA | NCT02559622 | P3 | completed | Psoriasis | 151 | — |
| GPP | NCT01952015 | P3 | completed | Psoriasis | 12 | — |
| SCALP | NCT02267135 | P3 | completed | Chronic Scalp Psoriasis | 102 | — |
| REASSURE | NCT01377012 | P3 | completed | Rheumatoid Arthritis | 637 | PMID 29138986 |
| REASSURE2 | NCT01770379 | P3 | terminated | Rheumatoid Arthritis | 242 | — |
| MEASURE 1 | NCT01358175 | P3 | completed | Ankylosing Spondylitis | 371 | PMID 28544533 |
| FUTURE 1 | NCT01392326 | P3 | completed | Psoriatic Arthritis | 606 | PMID 27169431 |
| FIXTURE | NCT01358578 | P3 | completed | Chronic Plaque Psoriasis | 1,306 | PMID 34110605 |
| STATURE | NCT01412944 | P3 | completed | Plaque-type Psoriasis | 43 | — |
| ERASURE | NCT01365455 | P3 | completed | Moderate to Severe Plaque-type Psoriasis | 738 | PMID 37341961 |
| STARS | NCT07477795 | P2 | not yet recruiting | Takayasu Arteritis | 52 | — |
| PRELUDE | NCT04300296 | P2 | completed | Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris | 111 | PMID 36197049 |
| TitAIN | NCT03765788 | P2 | completed | Giant Cell Arteritis | 52 | PMID 34404463 |
| NLD | NCT03791060 | P2 | terminated | Necrobiosis Lipoidica Diabeticorum | 4 | — |
| COLORIT | NCT04403243 | P2 | completed | COVID 19 | 70 | PMID 34658014 |
| Secu_in_AD | NCT03568136 | P2 | completed | Dermatitis, Atopic | 22 | — |
| SATURN | NCT02854163 | P2 | completed | Psoriatic Arthritis | 30 | — |
| PSARTROS | NCT02483234 | P2 | completed | Psoriasis | 40 | PMID 32907626 |
| RA | NCT01426789 | P2 | completed | Rheumatoid Arthritis | 100 | PMID 26268815 |
| AIN457 | NCT01250171 | P2 | completed | Dry Eye | 72 | — |
Terminated and withdrawn Secukinumab trials (16)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05206591withdrawnStudy to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
- NCT05722522terminatedStudy of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- NCT05758415terminatedStudy of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
- NCT04181762terminatedStudy of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
- NCT05232864terminatedOpen-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
- NCT04737330terminatedA Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
- NCT04274166withdrawnSecukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
- NCT04237116terminatedA Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
- NCT03866317withdrawnA Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
- NCT03791060terminatedSecukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
- NCT04488185withdrawnAn Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
- NCT02795416withdrawnAssessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population
- NCT02599129terminatedA Study of Secukinumab for the Treatment of Alopecia Areata
- NCT01770379terminatedSecukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
- NCT01478360terminatedSafety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma
- NCT02044848terminatedStudy of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
All Secukinumab trials (170)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06751238 | PK | Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). | P1 | recruiting | 20 | Novartis Pharmaceuticals | Sep 2025 |
| NCT07237594 | REPLAY | IL-17 Blockade to Decrease irAEs (REPLAY) | P1 | recruiting | 4 | Duke University | Mar 2026 |
| NCT07352566 | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis | P4 | not yet recruiting | 10 | University of California, San Francisco | Aug 2026 | |
| NCT04638647 | Secukinumab Open Label Roll-over Extension Protocol | P4 | recruiting | 1,000 | Novartis Pharmaceuticals | Dec 2020 | |
| NCT07477795 | STARS | Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients | P2 | not yet recruiting | 52 | Assistance Publique - Hôpitaux de Paris | Apr 2026 |
| NCT07489573 | Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa | P4 | recruiting | 36 | Novartis Pharmaceuticals | Jun 2026 | |
| NCT07485764 | Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients | P4 | not yet recruiting | 186 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Jun 2026 | |
| NCT05206591 | CAIN457X12301 | Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). | P3 | withdrawn | 0 | Novartis Pharmaceuticals | Aug 2022 |
| NCT06331312 | REPLENISH-EXT | Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) | P3 | active not recruiting | 161 | Novartis Pharmaceuticals | Jun 2024 |
| NCT05622708 | A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission | P4 | active not recruiting | 240 | Novartis Pharmaceuticals | Mar 2023 | |
| NCT06398106 | HELIOS | Proactive TDM Versus Standard Use of Biologics in Psoriasis | P4 | recruiting | 210 | University Hospital, Ghent | Dec 2024 |
| NCT06833112 | IL-17 | Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis | P4 | not yet recruiting | 10 | The Affiliated Hospital Of Guizhou Medical University | Feb 2025 |
| NCT04239859 | Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis | P4 | not yet recruiting | 40 | Singapore General Hospital | Jan 2024 | |
| NCT05503875 | Immunoclassification of Psoriasis: a Strategy for Precision Medicine | N/A | recruiting | 100 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Jan 2023 | |
| NCT06707246 | A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients | N/A | recruiting | 60 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Dec 2024 | |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | not yet recruiting | 80 | NYU Langone Health | Sep 2025 | |
| NCT07243782 | Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea | — | recruiting | 76 | Novartis Pharmaceuticals | Dec 2025 | |
| NCT06786936 | ELATE | Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms | — | recruiting | 50 | NHS Greater Glasgow and Clyde | Jun 2025 |
| NCT06945107 | A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy | P3 | active not recruiting | 308 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | May 2025 | |
| NCT07261072 | Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS | P4 | not yet recruiting | 30 | Peking Union Medical College | Dec 2025 | |
| NCT06905288 | ONSET | Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea. | — | recruiting | 70 | Novartis Pharmaceuticals | Apr 2025 |
| NCT05303285 | A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis | P4 | recruiting | 100 | Tongji Hospital | Jun 2024 | |
| NCT04179175 | Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa | P3 | active not recruiting | 703 | Novartis Pharmaceuticals | Mar 2020 | |
| NCT07254325 | Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers | P1 | active not recruiting | 114 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Dec 2025 | |
| NCT07109765 | Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa | — | recruiting | 50 | Peking Union Medical College | Jun 2025 | |
| NCT06398652 | Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis | P3 | completed | 336 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Aug 2024 | |
| NCT05380453 | GigAINt | Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission | P3 | completed | 151 | Novartis Pharmaceuticals | Sep 2022 |
| NCT04930094 | GCAptAIN | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) | P3 | completed | 354 | Novartis Pharmaceuticals | Oct 2021 |
| NCT05767034 | REPLENISH | Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) | P3 | completed | 381 | Novartis Pharmaceuticals | Mar 2023 |
| NCT04610476 | Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis | P3 | unknown | 270 | University of Erlangen-Nürnberg Medical School | Oct 2020 | |
| NCT06110676 | Psoriasis | A Study to Evaluate the Efficacy and Safety of LZM012 | P3 | unknown | 918 | Livzon Pharmaceutical Group Inc. | Aug 2023 |
| NCT06926192 | Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa | — | recruiting | 100 | Peking Union Medical College | Jan 2020 | |
| NCT04535999 | Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV) | P4 | completed | 16 | University of Pennsylvania | Feb 2022 | |
| NCT06130540 | Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR | P1 | completed | 65 | Novartis Pharmaceuticals | Mar 2024 | |
| NCT04717466 | Brain Changes in Psoriasis After Secukinumab Treatment | P4 | completed | 20 | University of Miami | Jun 2021 | |
| NCT04732117 | Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis | P3 | completed | 137 | Novartis Pharmaceuticals | Jul 2021 | |
| NCT04340076 | BeNeBio | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | P4 | completed | 244 | Radboud University Medical Center | Aug 2020 |
| NCT05527444 | The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients | P4 | unknown | 100 | Qilu Hospital of Shandong University | Mar 2022 | |
| NCT05569174 | UnchAIN | Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy | P3 | completed | 62 | Novartis Pharmaceuticals | Dec 2022 |
| NCT05722522 | Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy | P3 | terminated | 33 | Novartis Pharmaceuticals | Aug 2023 | |
| NCT05758415 | Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy | P3 | terminated | 60 | Novartis Pharmaceuticals | Aug 2023 | |
| NCT03769168 | ERA | An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) | P3 | completed | 55 | Novartis Pharmaceuticals | Jun 2019 |
| NCT04632927 | AgAIN | Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment | P3 | completed | 119 | Novartis Pharmaceuticals | Dec 2020 |
| NCT03445845 | ROC-SPA | Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis | P4 | completed | 300 | Centre Hospitalier Universitaire de Saint Etienne | Dec 2018 |
| NCT06126718 | Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects | P1 | completed | 88 | BioRay Pharmaceutical Co., Ltd. | Feb 2024 | |
| NCT05080218 | COVER | COVID-19 VaccinE Response in Rheumatology Patients | P4 | completed | 841 | Jeffrey Curtis | Nov 2021 |
| NCT02144857 | Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis | P4 | unknown | 200 | University of Athens | May 2014 | |
| NCT06391996 | Biologic Therapy for Generalized Pustular Psoriasis | — | completed | 65 | Chao Ji | Jul 2019 | |
| NCT04894890 | UNMASK2 | A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China | — | completed | 1,002 | Novartis Pharmaceuticals | Sep 2021 |
| NCT06600009 | FLYWAY | Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database | — | completed | 534 | Novartis | Oct 2022 |
| NCT04181762 | SELUNE | Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis | P3 | terminated | 275 | Novartis Pharmaceuticals | Jul 2020 |
| NCT03668613 | Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis | P3 | completed | 84 | Novartis Pharmaceuticals | Aug 2018 | |
| NCT05232864 | Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis | P3 | terminated | 31 | Novartis Pharmaceuticals | Aug 2022 | |
| NCT03536884 | BE RADIANT | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | P3 | completed | 743 | UCB Biopharma SRL | Jun 2018 |
| NCT05734482 | Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers | P1 | completed | 130 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Feb 2023 | |
| NCT03020199 | STEPin | Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis | P4 | completed | 196 | Novartis Pharmaceuticals | Mar 2017 |
| NCT04996485 | Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children | P4 | unknown | 50 | National Medical Research Center for Children's Health, Russian Federation | Mar 2021 | |
| NCT04737330 | ORBIT | A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) | P3 | terminated | 28 | Novartis Pharmaceuticals | Nov 2021 |
| NCT02471144 | Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis | P3 | completed | 162 | Novartis Pharmaceuticals | Sep 2015 | |
| NCT04967950 | An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients | P1 | unknown | 60 | Peking Union Medical College Hospital | Jul 2021 | |
| NCT04469829 | Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome | P4 | unknown | 70 | Universita di Verona | Aug 2020 | |
| NCT04156620 | Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA | P3 | completed | 527 | Novartis Pharmaceuticals | Dec 2019 | |
| NCT05583604 | Managed Access Programs for AIN457, Secukinumab | — | available | 0 | Novartis Pharmaceuticals | — | |
| NCT03623867 | PsA Secukinumab XCT Structural Progression Study | P4 | completed | 40 | Chinese University of Hong Kong | May 2020 | |
| NCT04887597 | EBIO | EBIO - Enthesitis Biopsy Study | P4 | unknown | 10 | University of Erlangen-Nürnberg Medical School | Mar 2019 |
| NCT03906136 | AScalate | AScalate: Treat-to-target in Axial Spondyloarthritis | P3 | completed | 304 | Novartis Pharmaceuticals | Jun 2019 |
| NCT03713619 | SUNSHINE | This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). | P3 | completed | 544 | Novartis Pharmaceuticals | Jan 2019 |
| NCT03713632 | SUNRISE | Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) | P3 | completed | 545 | Novartis Pharmaceuticals | Feb 2019 |
| NCT05891964 | Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital. | P4 | completed | 50 | Jinnah Postgraduate Medical Centre | Jul 2021 | |
| NCT03440736 | METABOLYX | Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome | P4 | completed | 781 | Novartis Pharmaceuticals | Feb 2018 |
| NCT04300296 | PRELUDE | PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus | P2 | completed | 111 | Novartis Pharmaceuticals | Jul 2020 |
| NCT04274166 | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | P2 | withdrawn | 0 | Wake Forest University Health Sciences | May 2021 | |
| NCT04571567 | A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis | P4 | completed | 20 | Saakshi Khattri | Dec 2019 | |
| NCT05677542 | Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study | — | completed | 758 | Novartis Pharmaceuticals | Jun 2021 | |
| NCT04414605 | Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis | Early P1 | unknown | 10 | Guangdong Provincial Hospital of Traditional Chinese Medicine | Jun 2020 | |
| NCT03307447 | OCT | Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). | P4 | unknown | 30 | Narrows Institute for Biomedical Research | Dec 2017 |
| NCT05650060 | Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis | — | completed | 163 | Novartis Pharmaceuticals | Jan 2021 | |
| NCT05513014 | Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis | — | completed | 1,518 | Novartis Pharmaceuticals | Mar 2021 | |
| NCT04237116 | pINPOINt | A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) | P3 | terminated | 10 | Novartis Pharmaceuticals | Feb 2020 |
| NCT03955861 | Ultrasound Enthesitis Response in Psoriatic Arthritis | — | completed | 80 | Belfast Health and Social Care Trust | Feb 2019 | |
| NCT03866317 | A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus | P2 | withdrawn | 0 | Massachusetts General Hospital | Sep 2019 | |
| NCT03131570 | Safety and Efficacy of Secukinumab in Mild Psoriasis | P2 | completed | 23 | James G. Krueger, MD, PhD | May 2017 | |
| NCT03765788 | TitAIN | A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis | P2 | completed | 52 | Novartis Pharmaceuticals | Jan 2019 |
| NCT03350815 | ASLeap | Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis | P4 | completed | 322 | Novartis Pharmaceuticals | Mar 2018 |
| NCT03791060 | NLD | Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD) | P2 | terminated | 4 | Beth Israel Deaconess Medical Center | Apr 2019 |
| NCT05320159 | Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab) | — | completed | 17,743 | Novartis Pharmaceuticals | Feb 2021 | |
| NCT04488185 | INTERCEPT | An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound | P4 | withdrawn | 0 | Novartis Pharmaceuticals | Nov 2020 |
| NCT02696031 | PREVENT | Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis | P3 | completed | 555 | Novartis Pharmaceuticals | Apr 2016 |
| NCT03639740 | TRACE | Treat-to-target With Secukinumab in Axial Spondyloarthritis | P4 | unknown | 88 | Professor Mikkel Østergaard | Jan 2019 |
| NCT02662985 | PDUS | Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) | P3 | completed | 166 | Novartis Pharmaceuticals | Aug 2016 |
| NCT03031782 | ERA | Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) | P3 | completed | 86 | Novartis Pharmaceuticals | May 2017 |
| NCT03041038 | The Efficacy and Safety of Secukinumab in Patients With Ichthyoses | P2 | completed | 20 | Northwestern University | Dec 2016 | |
| NCT04403243 | COLORIT | COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19 | P2 | completed | 70 | Lomonosov Moscow State University Medical Research and Educational Center | May 2020 |
| NCT03589885 | MATURE | Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis | P3 | completed | 122 | Novartis Pharmaceuticals | Dec 2018 |
| NCT03504852 | Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis | P3 | completed | 331 | Novartis Pharmaceuticals | Jun 2018 | |
| NCT03478787 | Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis | P3 | completed | 327 | AbbVie | May 2018 | |
| NCT03535194 | OASIS-2 | A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) | P3 | completed | 1,484 | Eli Lilly and Company | Jun 2018 |
| NCT03568136 | Secu_in_AD | Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis | P2 | completed | 22 | GWT-TUD GmbH | Sep 2018 |
| NCT03384745 | A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis | P2 | completed | 313 | Bond Avillion 2 Development LP | Jul 2018 | |
| NCT02745080 | EXCEED 1 | Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis | P3 | completed | 853 | Novartis Pharmaceuticals | Apr 2017 |
| NCT02771210 | ACHILLES | Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site | P3 | completed | 204 | Novartis Pharmaceuticals | Aug 2016 |
| NCT03344640 | Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy | P2 | completed | 96 | Novartis Pharmaceuticals | Dec 2017 | |
| NCT02763046 | ASTRUM | Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis | P4 | completed | 211 | Novartis Pharmaceuticals | May 2016 |
| NCT02733094 | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum | P1/P2 | completed | 8 | Technical University of Munich | Apr 2016 | |
| NCT02854163 | SATURN | Effect of Secukinumab in the Treatment of Psoriatic Arthritis | P2 | completed | 30 | University of Liverpool | Oct 2016 |
| NCT03149900 | BIOMARKER | Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients | — | completed | 40 | Diamant Thaci | Oct 2016 |
| NCT02721966 | MAXIMISE | Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement | P3 | completed | 503 | Novartis Pharmaceuticals | Oct 2016 |
| NCT03828643 | Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis | — | completed | 156 | Universita di Verona | Mar 2019 | |
| NCT02896127 | Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis | P3 | completed | 458 | Novartis Pharmaceuticals | Oct 2016 | |
| NCT03055494 | ObePso-S | Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients | P4 | completed | 102 | Novartis Pharmaceuticals | Apr 2017 |
| NCT05676333 | Secukinumab in Active Non-segmental Vitiligo | P4 | completed | 8 | University Hospital, Ghent | Oct 2016 | |
| NCT03099980 | Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa | Early P1 | completed | 20 | Tufts Medical Center | Jul 2016 | |
| NCT03079531 | Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea | P1/P2 | completed | 24 | Anne Chang | Jun 2017 | |
| NCT02404350 | FUTURE5 | Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis | P3 | completed | 997 | Novartis Pharmaceuticals | Aug 2015 |
| NCT01752634 | FUTURE 2 | Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis | P3 | completed | 397 | Novartis Pharmaceuticals | Apr 2013 |
| NCT02592018 | Immunologic Response to Secukinumab in Plaque Psoriasis | P4 | completed | 15 | University of California, San Francisco | Oct 2016 | |
| NCT02798211 | Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo | P4 | completed | 258 | Novartis Pharmaceuticals | Jun 2016 | |
| NCT03066609 | Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis | P3 | completed | 543 | Novartis Pharmaceuticals | Feb 2017 | |
| NCT02483234 | PSARTROS | Psoriasis-Arthritis & Bone Program | P2 | completed | 40 | University of Erlangen-Nürnberg Medical School | May 2015 |
| NCT03090100 | ECLIPSE | A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis | P3 | completed | 1,048 | Janssen Research & Development, LLC | Apr 2017 |
| NCT01649375 | MEASURE2 | 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis | P3 | completed | 219 | Novartis Pharmaceuticals | Oct 2012 |
| NCT02826603 | CLARITY | Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis | P3 | completed | 1,114 | Novartis Pharmaceuticals | Jun 2016 |
| NCT02748863 | ALLURE | Study of Secukinumab With 2 mL Pre-filled Syringes | P3 | completed | 214 | Novartis Pharmaceuticals | Dec 2016 |
| NCT02750592 | Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis | P3 | completed | 30 | Novartis Pharmaceuticals | Mar 2016 | |
| NCT02752776 | PROSE | A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. | P4 | completed | 1,660 | Novartis Pharmaceuticals | Mar 2016 |
| NCT01989468 | 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis | P3 | completed | 414 | Novartis Pharmaceuticals | Apr 2014 | |
| NCT01863732 | MEASURE 1 ext | Extension in AS: Sustainability of Benefits, Safety and Tolerability | P3 | completed | 274 | Novartis Pharmaceuticals | Nov 2013 |
| NCT02690701 | VIP-S | Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis | P4 | completed | 91 | Novartis Pharmaceuticals | Feb 2016 |
| NCT02594098 | Secukinumab for Treatment of Atopic Dermatitis | P2 | completed | 41 | Icahn School of Medicine at Mount Sinai | Nov 2015 | |
| NCT01892436 | FUTURE 1 ext | Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis | P3 | completed | 460 | Novartis Pharmaceuticals | Sep 2013 |
| NCT02159053 | MEASURE4 | 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis | P3 | completed | 350 | Novartis Pharmaceuticals | May 2015 |
| NCT02294227 | FUTURE 4 | 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis | P3 | completed | 341 | Novartis Pharmaceuticals | May 2015 |
| NCT02008916 | MEASURE 3 | 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients | P3 | completed | 226 | Novartis Pharmaceuticals | Jan 2014 |
| NCT03358134 | MoA aIL-17 | Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis | P3 | completed | 20 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Mar 2014 |
| NCT02778711 | Anti-IL-17 a New Treatment for Contact Dermatititis | P3 | unknown | 20 | Tanja Todberg, MD | Jan 2016 | |
| NCT01544595 | Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab | P3 | completed | 1,147 | Novartis Pharmaceuticals | Jun 2012 | |
| NCT02394561 | SUPREME | A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) | P3 | completed | 434 | Novartis Pharmaceuticals | Apr 2015 |
| NCT02008890 | Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab | P3 | completed | 237 | Novartis Pharmaceuticals | Dec 2013 | |
| NCT02409667 | OPTIMISE | Plaque Psoriasis Efficacy and Safety With Secukinumab | P3 | completed | 16,487 | Novartis Pharmaceuticals | May 2015 |
| NCT02795416 | Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population | P3 | withdrawn | 0 | Novartis Pharmaceuticals | Jun 2016 | |
| NCT02595970 | IPSI-PSO | Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis | P3 | completed | 120 | Novartis Pharmaceuticals | May 2015 |
| NCT01807520 | TRANSFIGURE | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis | P3 | completed | 198 | Novartis Pharmaceuticals | Jun 2013 |
| NCT02599129 | A Study of Secukinumab for the Treatment of Alopecia Areata | P2 | terminated | 11 | Icahn School of Medicine at Mount Sinai | Nov 2015 | |
| NCT01806597 | GESTURE | Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis | P3 | completed | 205 | Novartis Pharmaceuticals | Jun 2013 |
| NCT01636687 | JUNCTURE | Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) | P3 | completed | 182 | Novartis Pharmaceuticals | Oct 2012 |
| NCT01555125 | FEATURE | First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks | P3 | completed | 177 | Novartis Pharmaceuticals | May 2012 |
| NCT02474069 | GAIN | Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis | P3 | completed | 772 | Novartis Pharmaceuticals | Feb 2015 |
| NCT02362789 | PSORITUS | Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers | P3 | completed | 132 | Novartis Pharmaceuticals | Jan 2015 |
| NCT01961609 | SIGNATURE | Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. | P3 | completed | 235 | Novartis Pharmaceuticals | Oct 2013 |
| NCT02474082 | PRIME | Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. | P3 | completed | 202 | Novartis Pharmaceuticals | Apr 2015 |
| NCT02074982 | Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis | P3 | completed | 676 | Novartis Pharmaceuticals | Feb 2014 | |
| NCT02547714 | Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A | P4 | completed | 34 | Novartis Pharmaceuticals | Jun 2015 | |
| NCT02559622 | CARIMA | Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab | P3 | completed | 151 | Novartis Pharmaceuticals | Apr 2014 |
| NCT01952015 | GPP | Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) | P3 | completed | 12 | Novartis Pharmaceuticals | Aug 2013 |
| NCT02267135 | SCALP | Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis | P3 | completed | 102 | Novartis Pharmaceuticals | Sep 2014 |
| NCT01828086 | Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis | P1 | completed | 95 | Novartis Pharmaceuticals | Jun 2013 | |
| NCT01377012 | REASSURE | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents | P3 | completed | 637 | Novartis Pharmaceuticals | Aug 2011 |
| NCT01770379 | REASSURE2 | Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents. | P3 | terminated | 242 | Novartis Pharmaceuticals | Oct 2012 |
| NCT01537432 | Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients | P2 | completed | 36 | Novartis Pharmaceuticals | Jan 2012 | |
| NCT01358175 | MEASURE 1 | 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis | P3 | completed | 371 | Novartis Pharmaceuticals | Oct 2011 |
| NCT01478360 | Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma | P2 | terminated | 46 | Novartis Pharmaceuticals | Mar 2012 | |
| NCT01392326 | FUTURE 1 | Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) | P3 | completed | 606 | Novartis Pharmaceuticals | Sep 2011 |
| NCT02044848 | Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus | P2 | terminated | 5 | Novartis Pharmaceuticals | Feb 2014 | |
| NCT01426789 | RA | A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients | P2 | completed | 100 | Novartis Pharmaceuticals | Aug 2011 |
| NCT01359943 | Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate | P2 | completed | 221 | Novartis Pharmaceuticals | Oct 2011 | |
| NCT01358578 | FIXTURE | Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis | P3 | completed | 1,306 | Novartis Pharmaceuticals | Jun 2011 |
| NCT01412944 | STATURE | Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis | P3 | completed | 43 | Novartis Pharmaceuticals | Dec 2011 |
| NCT01365455 | ERASURE | Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year | P3 | completed | 738 | Novartis Pharmaceuticals | Jun 2011 |
| NCT01539213 | OFM ISF | Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg | P1 | completed | 16 | Novartis Pharmaceuticals | Feb 2012 |
| NCT01250171 | AIN457 | The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients | P2 | completed | 72 | Novartis Pharmaceuticals | Nov 2010 |
Secukinumab clinical trials: frequently asked questions
- How many Secukinumab clinical trials are there?
- 170 Secukinumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 13 are actively recruiting participants. 116 are marked completed.
- Are Secukinumab clinical trials recruiting in 2026?
- Yes — 13 Secukinumab trials are actively recruiting in 2026, with 11 U.S. sites across 7 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Secukinumab being studied for?
- Secukinumab is being studied for Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Hidradenitis Suppurativa and 85 more. The trials are grouped by indication on this page.
- What phase is Secukinumab in?
- Secukinumab clinical trials span 37 Phase 4, 79 Phase 3, 23 Phase 2, 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Secukinumab clinical trials?
- The lead sponsor across the most Secukinumab trials is Novartis Pharmaceuticals, with 56 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Secukinumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: